Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 crore from Indian pharma giants

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has been reduced to ₹2,000 crore due to declining sales and government price cuts. Despite newer insulin options, Lantus remains a market leader in India's growing diabetes market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nwBe4oF
via IFTTT